Cure8 regulatory brief
FUT enzymes affect mucosal immunity and have been associated with Crohn's disease and other IBDs; understanding their function could reveal new biological mechanisms and future therapeutic targets.
Researchers studying mucosal immunology, glycobiology, and the microbiome; clinicians and translational scientists interested in IBD pathogenesis and novel biomarkers.
The project will use biochemistry, functional glycoproteomics, and cell biology to (1) map how FUTs influence mucosal immune cell populations, (2) investigate how glycan‑binding proteins on immune cells recognize fucosylated structures, and (3) develop a novel mass‑spectrometry toolkit to identify difficult FUT substrates.
Over the next five years the investigators plan to characterize molecular mechanisms by which fucosylation regulates tissue‑resident and recruited immune cells at mucosal surfaces and to create analytical tools that make previously hard‑to‑detect glycan modifications visible.
This is a funded research program description (NIH Reporter project record), not a clinical trial or treatment recommendation. It reports aims and planned methods rather than results.
This is a project-record summary of a funded basic‑science program describing planned research and tool development. It does not report study results or clinical implications; findings will require peer‑reviewed publication and further validation before clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
